Valiant Laboratories Limited: Certificate under SEBI (Depositories and Participants) Regulations, 2018
Valiant Laboratories Limited received a confirmation certificate for Q1 FY27 under SEBI (Depositories and Participants) Regulations, 2018. The RTA confirmed the regulation is not applicable as all securities are in dematerialized form, with no requests for dematerialization or cancellation received during the quarter ended June 30, 2026.
This is a standard regulatory compliance update and does not involve any new business developments, financial results, or strategic changes that would significantly impact the company's operations or stock price.
The announcement is a routine compliance filing and does not contain any information that would positively or negatively impact the company's stock.
Valiant Laboratories Limited has received a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. MUFG Intime India Private Limited, the Registrar and Share Transfer Agent (RTA) for the company, has confirmed that the said regulation is not applicable to Valiant Laboratories Limited.
This is because all the securities of the company are held in dematerialized form. Consequently, no requests for dematerialization, mutilation, or cancellation of securities were received by the company, its RTA, or any Depository Participants during the specified quarter. The company has informed the stock exchanges, BSE Limited and the National Stock Exchange of India Limited, about this update and has also uploaded the information on its website, www.valiantlabs.in.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.